Josh Sommer Named To Forbes' "30 Under 30" List

Congratulations to our good friend, Josh Sommer, Executive Director of the Chordoma Foundation, for making Forbes magazine's "30 Under 30" list!  The annual list is a who's who of the nation's top young disruptors, innovators and entrepreneurs. 

Josh was diagnosed with clival chordoma in 2006 while attending Duke University.  Chordoma is a rare type of cancer that occurs in the bones of the skull and spine.  Determined to find his own cure, Josh volunteered for two years in an oncology lab at Duke. In 2008, he received a two-year Echoing Green Fellowship for Social Entrepreneurs for his pioneering work in bridging patient advocacy and research. 

Josh founded his organization to unite patients, doctors and scientists to accelerate treatments for chordoma. He strongly believes that patients can and should play an active role in bringing about treatments for their own conditions.

When Max Wallace, CEO of Accelerate Brain Cancer Cure, first met Josh in 2008 he was impressed with Josh's entrepreneurial drive and singular focus.  They immediately bonded and considered themselves to be fellow soldiers in the fight against rare diseases.  As a result, the two organizations have built strategic alliances and worked together on a variety of rare disease initiatives. In 2010, Josh participated in our Annual Scientific Gathering.  In 2011, ABC2 and the Chordoma Foundation co-hosted a National Cancer Institute meeting of the Director's Consumer Liaison Group in Research Triangle Park, NC.

 

Newsletter Issue: 
Share |
July 25, 2014 10:51 AM
Guest blogger Lisa Peabody shares her personal story and her experience as an advocate at the recent Alliance for Childhood Cancer Action Day.
July 3, 2014 11:01 AM
ABC2 helped fund the early-stage research by Dr. Andrew Parsa that is now being developed by Agenus.
June 24, 2014 03:22 PM
Join us for the screening and meet Maria Parker, the inspiring cyclist profiled in the film.  Proceeds benefit 3000 Miles To A Cure in partnership with ABC2.

Join us in our fight for a cure!

Twitter